Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,500.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $5.70, for a total value of $28,500.00. Following the sale, the insider directly owned 228,387 shares of the company’s stock, valued at approximately $1,301,805.90. This represents a 2.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total transaction of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total transaction of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total transaction of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total transaction of $3,161.60.

SOPHiA GENETICS Stock Up 1.0%

SOPHiA GENETICS stock opened at $5.83 on Friday. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.30. The firm has a 50 day moving average price of $5.22 and a 200-day moving average price of $5.01. The company has a market capitalization of $489.08 million, a P/E ratio of -11.21 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million. SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.

Institutional Trading of SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the business. Perkins Capital Management Inc. purchased a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the 1st quarter valued at approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter valued at approximately $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter valued at $55,000. Institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

SOPH has been the subject of a number of recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and set a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and a consensus target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.